CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

December 15, 2023

https://www.globenewswire.com/news-release/2023/11/07/2775653/37704/en/CytomX-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html

– CX-904 (EGFRxCD3 T-cell engager) initial Phase 1 dose escalation data anticipated in the first half of 2024 –

– CX-2051 (EpCAM-directed ADC) comprehensive preclinical profile presented at 14th Annual World ADC Conference; IND filing on track for year-end –

Read more at globenewswire.com

Related news for (CTMX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.